Madrigal Historical Financial Ratios
| MDGL Stock | USD 312.00 1.13 0.36% |
Madrigal Pharmaceuticals is lately reporting on over 105 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 3.12 will help investors to properly organize and evaluate Madrigal Pharmaceuticals financial condition quickly.
Madrigal |
About Madrigal Financial Ratios Analysis
Madrigal PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Madrigal Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Madrigal financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Madrigal Pharmaceuticals history.
Madrigal Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Madrigal Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Madrigal Pharmaceuticals sales, a figure that is much harder to manipulate than other Madrigal Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Madrigal Pharmaceuticals dividend as a percentage of Madrigal Pharmaceuticals stock price. Madrigal Pharmaceuticals dividend yield is a measure of Madrigal Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Madrigal Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Madrigal Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' EV To Sales is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 75.06 this year, although Book Value Per Share will most likely fall to 20.61.
| 2023 | 2024 (projected) | Dividend Yield | 0.008267 | 0.007348 | Price To Sales Ratio | 3.3K | 3.4K |
Madrigal Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Madrigal Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Madrigal Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 3.37 | 7.16 | 7.15 | 25.2 | 10.67 | 11.2 | |
| Book Value Per Share | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 20.61 | |
| Free Cash Flow Yield | (0.0298) | (0.0919) | (0.13) | (0.0452) | (0.0753) | (0.0791) | |
| Operating Cash Flow Per Share | (2.7) | (10.2) | (11.12) | (13.12) | (17.35) | (18.22) | |
| Capex To Depreciation | 1.54 | 0.71 | 0.52 | 0.46 | 2.81 | 2.95 | |
| Pb Ratio | 3.37 | 7.16 | 7.15 | 25.2 | 10.67 | 11.2 | |
| Free Cash Flow Per Share | (2.71) | (10.22) | (11.14) | (13.13) | (17.43) | (18.3) | |
| Roic | (0.11) | (0.2) | (0.84) | (1.23) | (0.73) | (0.77) | |
| Net Income Per Share | (4.73) | (12.78) | (14.58) | (17.47) | (19.99) | (20.99) | |
| Payables Turnover | 0.0951 | 0.46 | 0.0189 | 0.0196 | 0.0188 | 0.0179 | |
| Cash Per Share | 28.52 | 18.4 | 16.35 | 20.94 | 33.93 | 32.24 | |
| Pocfratio | (33.7) | (10.9) | (7.62) | (22.12) | (13.34) | (14.0) | |
| Interest Coverage | (57.46) | (5.3) | (8.62) | (74.06) | (29.93) | (31.43) | |
| Capex To Operating Cash Flow | (0.004132) | (0.00212) | (0.001136) | (9.65E-4) | (0.004562) | (0.00479) | |
| Pfcf Ratio | (33.56) | (10.88) | (7.61) | (22.1) | (13.28) | (13.94) | |
| Days Payables Outstanding | 3.8K | 788.12 | 19.3K | 18.6K | 19.4K | 18.5K | |
| Income Quality | 0.72 | 0.78 | 0.5 | 0.76 | 0.87 | 0.55 | |
| Ev To Operating Cash Flow | (32.59) | (10.56) | (7.43) | (20.87) | (13.39) | (14.06) | |
| Pe Ratio | (19.26) | (8.7) | (5.81) | (16.62) | (11.57) | (12.15) | |
| Ev To Free Cash Flow | (32.46) | (10.54) | (7.42) | (20.85) | (13.33) | (14.0) | |
| Earnings Yield | (0.0519) | (0.11) | (0.17) | (0.0602) | (0.0864) | (0.0907) | |
| Net Debt To E B I T D A | 0.49 | 0.26 | 0.15 | 0.96 | (0.0455) | (0.0432) | |
| Current Ratio | 17.52 | 6.13 | 3.54 | 3.12 | 5.38 | 7.32 | |
| Tangible Book Value Per Share | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 20.61 | |
| Graham Number | 53.66 | 66.84 | 62.37 | 67.28 | 98.78 | 93.84 | |
| Shareholders Equity Per Share | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 20.61 | |
| Capex Per Share | 0.0112 | 0.0216 | 0.0126 | 0.0127 | 0.0791 | 0.0752 | |
| Graham Net Net | 26.86 | 15.35 | 11.68 | 11.3 | 21.35 | 20.28 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.